Sentences with phrase «first phase of the clinical trial»

«The first phase of clinical trials are tests of human safety, so this is a promising start,» Alvey said.

There is no vaccine yet, but the National Institutes of Health has entered the first phase of clinical trials for an investigational vaccine.

Not exact matches

In a research and strategy update, Novo said it will initiate a phase 3 clinical trial program with once - weekly subcutaneous semaglutide in obesity in the first half of 2018.

In a research and strategy update, Novo said it planned to start a final phase 3 clinical trial program with once - weekly subcutaneous semaglutide in obesity in the first half of 2018.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

The phase 1 clinical trial is the first to test the functional replacement of the mutated gene responsible for SMA1.

Promising results of an earlier, initial, multicenter clinical trial of nivolumab, first reported in 2013 and directed by Brahmer, led to the current phase III trial of 260 patients treated at hospitals across the world.

In March, researchers, in collaboration with the pharmaceutical company Ultragenyx, completed the first part of a Phase III clinical trial in adults with XLH — the final test of a drug before federal approval.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inclinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inClinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on April 19.

Sangamo biochemist Philip Gregory notes that this Phase 1 clinical trial is the first human test of an entirely new class of drug that could turn any gene on or off, depending on the disease.

Since CGP3466B has already been tested in phase II clinical trials to (unsuccessfully) treat Parkinson's disease and ALS, it is known to be safe for humans, but the researchers caution that many more years of studies are needed to definitively show whether it is effective for preventing cocaine damage, first in mice, then in humans.

«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»

The first such drug, torcetrapib, was abandoned after a phase 3 clinical trial revealed it increased the risk of cardiovascular events and death.

Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 mg twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).

PHILADELPHIA --(April 19, 2018)-- The Wistar Institute and partners at the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their ground - breaking phase 1 DNA - based Zika vaccine research — the first trial of a Zika vaccine in humans, which proved safe and effective.

Andy has over 10 years of experience in clinical trial management, specializing in early phase, first - in - human, global studies.

The Human Trial is following one research team and a handful of trial patients as they move from the lab through the first two years of the Phase 1/2 clinical tTrial is following one research team and a handful of trial patients as they move from the lab through the first two years of the Phase 1/2 clinical ttrial patients as they move from the lab through the first two years of the Phase 1/2 clinical trialtrial.

As reviewed in our previous post, AFFiRiS announced the initiation of the first Phase I clinical trial of PD01A in June of 2012.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

A University of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a first - in - human phase I clinical trial combining adoptive cell transfer of a T cell receptor engineered to recognize NY - ESO - 1 along with Yervoy ® (ipilimumab, anti-CTLA-4).

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

Its Clinical Trials Center conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea laClinical Trials Center conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea laclinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea laclinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea last year.

Clinical Trials Research and Billing First in Human / Early Phase PET in Oncology Case - Based Dose Reduction in Pediatric Nuclear Medicine: Practical and Necessary Radioiodine Therapy for Hyperthyroidism: The State of the Art Spondylodiscitis: Role of Imaging for Diagnosis and Monitoring Treatment Response Current Status and Future Prospects: PET and SPECT Instrumentation Alternative Payment Models and Value - Based Health Care: Nuts and Bolts Maximal Tolerated Activity of Radioactive Iodine for Metastatic Thyroid Cancer Teaching Old Radiopharmaceuticals New Tricks Intraoperative Detection Devices and Probes Molecular Imaging of Lung Inflammation Standardization of Advanced PET / SPECT Data Acquisition and Analysis Thyroid Cancer Management: Novel Therapeutics and Management Options Targeting Radionuclide Therapy in Various Non-Malignant Arthritic Conditions Using Radiosynoviorthesis (RSO) Are You Prepared for a Radiation Accident?

Dr. Caskey and her team describe the first in human, phase 1 clinical trial of a first in class fully human highly neutralizing anti-HIV monoclonal antibody.

The approval came on the heels of the first phase III clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival of 10.1 months, versus 6.4 months in the control group.

Our program offers access to Phase I clinical trials and First - in - children protocols available only at a very limited number of institutions.

A so - called Phase I clinical trial is when a new drug or a new formulation of a drug, or a new combination therapy for that matter, is tested in humans for the first time.

The first trial to take place as a result of the CDP initiative is a Phase I clinical trial of GlaxoSmithKline's aurora kinase inhibitor GSK - 1070916A - a promising new drug to treat solid tumours.

Essentially, Roche has committed to paying Isis $ 30 million for the development of its Huntington's disease drugs and the first «phase 1» clinical trial in patients.

In September 2016, we announced the first clinical application of our GLAAS discovery platform in Sanofi's Phase 1 clinical trial evaluating a novel therapeutic candidate for the treatment of peanut allergy.

The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new results from a phase I trial to be presented at the AACR Annual Meeting 2015 on Sunday, April 19 (Abstract #CT137).

Phase zero — the first example of a new pre-phase-I clinical trial came from the National Cancer Institute for a drug in Abbott's pipelinine.